Method for producing dendritic cell formulation including dendritic cells that stimulate NKT cells

JPWO2024085085A5Active Publication Date: 2024-11-15DC-BIOTECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024551777
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-13
Filing Date
2023-10-13
Publication Date
2024-11-15
Estimated Expiration
2043-10-13

AI Technical Summary

Technical Problem

Current methods for producing dendritic cell preparations that stimulate NKT cells are limited in their ability to induce high levels of IFN-γ production and do not optimize the timing of dendritic cell maturation and NKT cell stimulation, affecting their therapeutic efficacy in cancer treatment and immunity enhancement.

Method used

A method involving the pulsing of α-galactosylceramide to immature dendritic cells at specific timings to enhance IFN-γ production, with the concentration of α-galactosylceramide ranging from 300 to 1000 ng/mL, and the use of GM-CSF, IL-4, and OK-432 to mature dendritic cells, optimizing the immune response.

Benefits of technology

This approach significantly increases IFN-γ production, activating both innate and adaptive immune systems, leading to enhanced therapeutic effects in cancer treatment and improved immunity, with the dendritic cell preparation being safer due to its autologous nature.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

[Problem] To provide a method for producing a dendritic cell formulation that stimulates NKT cells, from monocytes collected from a recipient (monocytes collected by apheresis or peripheral blood containing monocytes), and that can exhibit the effect more quickly than conventional products. [Solution] This method for producing a dendritic cell formulation comprises: an adhesion step for placing collected monocytes in a culture vessel using a liquid culture medium, and leaving the culture vessel still to cause a portion of the monocytes to adhere to the inner surface of the vessel; a non-adhering cell removal step for removing non-adhering cells including monocytes other than the cells adhering to the inner surface of the culture vessel; a differentiation step for adding a predetermined factor in the culture vessel to cause the monocytes adhering to the inner surface of the culture vessel to differentiate into immature dendritic cells; a pulsing step for performing, with α-galactosylceramide, pulsing in the culture vessel in which the immature dendritic cells are present in a non-adhering state; and an NKT-stimulating dendritic cell induction step for inducing, from the immature dendritic cells, NKT-stimulating dendritic cells that stimulate NKT cells. The dendritic cell formulation is administered back into a recipient from which the blood have been collected.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing a dendritic cell preparation comprising dendritic cells that stimulate NKT cells

[0001] The present invention relates to a method for producing a dendritic cell preparation consisting of dendritic cells that stimulate NKT cells ("T" stands for thymus) with fewer side effects, which is used for one or more of cancer treatment, cancer prevention, and improving the immune system of healthy individuals. In particular, the present invention relates to a method for producing a dendritic cell preparation based on cells collected from the beneficiary himself / herself, and to blood to which the dendritic cell preparation produced by this method has been added.

[0002] In recent years, cancer immunotherapy or methods for improving the immune system of healthy individuals that target NKT cells have been developed. This therapy does not target cancer cells themselves, but activates NKT cells, the command center of the immune system. The adjuvant effect of activated NKT cells (activating some immune system cells promotes the activation of other immune system cells, activating the immune system comprehensively) produces a strong antitumor effect. Furthermore, because it is not limited to targeting specific antigens, it is expected to be effective against new mutated cancer cells as well as non-cancer pathogens such as bacteria, viruses, and parasites.

[0003] Patent Document 1 describes a method in which monocytes are placed in a first culture vessel and allowed to stand to allow a portion of the monocytes to settle on the bottom of the vessel, and non-adherent cells other than those adhered to the bottom of the vessel are collected and stored. Of the remaining cells adhering to the bottom, the monocytes are subjected to a predetermined treatment to differentiate into immature dendritic cells, which are then subjected to a further predetermined treatment to mature them. α-Galactosylceramide (hereinafter referred to as α-Galactosylceramide) is then added to the mature dendritic cells, and dendritic cells that stimulate NKT cells are induced from the mature dendritic cells. These dendritic cells are then placed in a second culture vessel together with the preserved non-adherent cells and cultured to induce NKT cells from a portion of the non-adherent cells.

[0004] Patent No. 6854290

[0005] Patent Document 1 describes that when NKT cells are activated, they produce large amounts of IFN-γ (interferon gamma), and that when CD-1d molecules are presented on the surface of antigen-presenting cells (dendritic cells), an activation signal is transmitted via the T cell receptor on the surface of the NKT cells, thereby activating the NKT cells.

[0006] Patent Document 1 discloses a cell composition containing NKT cells and dendritic cells that stimulate NKT cells, and the percentage of NKT cells is shown, but does not disclose the amount of IFN-γ produced, which produces various effects on cancer cells, so its effect cannot be said to be clear. Furthermore, it states that induction to stimulate NKT cells is performed after the dendritic cells have matured. However, there is no description examining the temporal relationship between the timing of induction and the timing of maturation.

[0007] In order to solve these problems, the present inventors have conducted research and development and discovered a preparation of the present invention that produces a greater amount of IFN-γ and initiates IFN-γ production more quickly than the method of Patent Document 1. As a result of examining the timing of inducing dendritic cells to stimulate NKT cells, the present invention is able to produce a greater amount of IFN-γ by NKT cells than the prior art (Patent Document 1). The produced IFN-γ stimulates and activates both the innate and adaptive immune system pathways in the human body, and therefore, greater effects from both pathways stimulated by the large amount of IFN-γ can be expected in cancer treatment and other conditions, and the present invention provides a method for producing a dendritic cell preparation consisting of dendritic cells that stimulate NKT cells, which can be expected to have a greater therapeutic effect.

[0008] First, to summarize the means for solving the problem, the effect is greater when the pulsing timing of the ligand to dendritic cells is performed when the dendritic cells are immature. Furthermore, the timing of pulsing the ligand to immature dendritic cells is not necessarily any time as long as the dendritic cells are immature; even when the dendritic cells are immature, significant effects can be obtained by pulsing at a specific timing. Specific means for solving the problem are described below.

[0009] In order to solve the above-mentioned problems related to dendritic cell preparations, the first invention of the present application is a method for producing a dendritic cell preparation consisting of dendritic cells that stimulate natural killer T (NKT) cells for the purpose of one or more of cancer treatment, cancer prevention, and immune enhancement, comprising: (1) an adhesion step of placing monocytes collected from a recipient (apheresis or collected monocytes or monocyte-containing peripheral blood) into a culture vessel using a liquid medium and leaving it to stand to allow some of the monocytes to adhere to the inner surface of the vessel; (2) a non-adherent cell removal step of removing non-adherent cells including monocytes other than those adhered to the inner surface of the culture vessel; (3) a differentiation step of adding a predetermined factor to the culture vessel to differentiate the monocytes adhered to the inner surface of the culture vessel into immature dendritic cells; and (4) a pulsing step of pulsing α-galactosylceramide into the culture vessel in which the immature dendritic cells exist in a non-adherent state. (5) A method for producing a dendritic cell preparation that stimulates NKT cells to be infused back into the body of the beneficiary from whom the monocytes were collected, the method comprising: an NKT-stimulating dendritic cell induction step of inducing NKT-stimulating dendritic cells, which are dendritic cells that stimulate NKT cells, from immature dendritic cells.

[0010] Furthermore, as a second invention, based on the first invention, there is provided a method for producing a dendritic cell preparation, in which the pulsing step (4) of the first invention is carried out on day 3 or 4, with the day on which a predetermined factor is added in the differentiation step (3) being considered day 0.

[0011] Furthermore, as a third invention, based on the first invention, there is provided a method for producing a dendritic cell preparation, in which the pulsing step (4) of the first invention is carried out 60 to 108 hours after adding a predetermined factor in the differentiation step (3).

[0012] Furthermore, as a fourth invention, based on the first invention, there is provided a method for producing a dendritic cell preparation according to claim 1, in which the pulsing step (4) is carried out by the fourth or fifth day, with the day on which monocytes collected from the recipient in the adhesion step (1) are placed in a culture vessel being considered as day 0.

[0013] Furthermore, as a fifth invention, based on the first invention, there is provided a method for producing a dendritic cell preparation, in which the pulsing step (4) is carried out 84 to 132 hours after the monocytes collected from the recipient in the adhesion step (1) are placed in a culture vessel.

[0014] Furthermore, as a sixth invention, based on the first invention, there is provided a method for producing a dendritic cell preparation, in which the pulsing step (4) is performed on the fourth or fifth day, with the day on which non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel are removed in the non-adherent cell removal step (2), being considered as day 0.

[0015] Furthermore, as a seventh invention, based on the first invention, there is provided a method for producing a dendritic cell preparation, in which the pulsing step (4) is carried out between 84 hours and 132 hours after the removal of non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel in the non-adherent cell removal step (2).

[0016] Furthermore, as an eighth invention, there is provided a method for producing a dendritic cell preparation based on any one of the first to seventh inventions, in which the concentration of α-galactosylceramide pulsed in the pulsing step (4) is 300 to 1000 ng / mL.

[0017] Furthermore, as a ninth invention, the blood of a recipient to which a dendritic cell preparation produced by the production method according to any one of the first to seventh inventions has been added is provided.

[0018] Furthermore, as a tenth aspect of the present invention, the blood of a recipient to which a dendritic cell preparation produced by the production method described in the eighth aspect of the present invention has been added is provided.

[0019] According to the method of the present invention for producing a dendritic cell preparation that stimulates NKT cells, in which monocytes are returned to the body of a recipient from whom the monocytes were collected, it is possible to produce a greater amount of IFN-γ by NKT cells than in the prior art (Patent Document 1). The produced IFN-γ stimulates and activates both the innate and adaptive immune system pathways in the human body, and therefore, greater effects from both pathways stimulated by the large amount of IFN-γ produced can be expected in cancer treatment and the like, and the present invention provides a method for producing a dendritic cell preparation consisting of dendritic cells that stimulate NKT cells, which can be expected to have a greater therapeutic effect.

[0020] Graph showing the relationship between the pulse timing of α-galactosylceramide during the production of a dendritic cell preparation of embodiment 2 and the ratio of NKT cells to the number of cells after co-culture. Graph 1 showing the relationship between the pulse timing of α-galactosylceramide during the production of a dendritic cell preparation of embodiment 2 and the maximum ratio of NKT cells to the number of cells after co-culture under each condition (when the day of addition of a predetermined factor for differentiation is set to day 0). Graph 2 showing the relationship between the pulse timing of α-galactosylceramide during the production of a dendritic cell preparation of embodiment 2 and the maximum ratio of NKT cells to the number of cells after co-culture under each condition (when the start of culture is used as the starting point). Graph showing the relationship between the pulse timing of α-galactosylceramide during the production of a dendritic cell preparation of embodiment 3 and the ratio of NKT cells to the number of cells after co-culture. Graph 1 shows the relationship between the timing of α-galactosylceramide pulse during the production of a dendritic cell preparation and the maximum ratio of NKT cell numbers after co-culture under each condition (when the day of addition of a specific differentiation factor is set to day 0). Graph 2 shows the relationship between the timing of α-galactosylceramide pulse during the production of a dendritic cell preparation of embodiment 3 and the maximum ratio of NKT cell numbers after co-culture under each condition (when the start of culture is used as the starting point). Graph showing the relationship between the concentration of α-galactosylceramide pulsed during the production of a dendritic cell preparation of embodiment 4 and the amount of IFN-γ produced after co-culture. NK cell activity value and amount of IFN-γ produced when a dendritic cell preparation of the present invention is used in the human body. Comparison of the effects of the prior art (Patent Document 1) and the present invention (amount of IFN-γ produced after co-culture).

[0021] First, before describing the embodiments of the present invention, we will explain the body's immunity. In the following specification, we will explain the effect of the formulation of the present invention on cancer cells as an example, but similar effects can be obtained against other pathogens, etc. Immunity can be divided into innate immunity, which an organism originally has, and adaptive immunity, which an organism acquires later.

[0022] Innate immunity is a type of immunity that is present in the human body from birth, and is composed primarily of phagocytes that ingest and eliminate foreign substances such as bacteria and viruses. Phagocytes have receptors that recognize molecules and structures, and are broadly divided into types that process and eliminate foreign substances, and types that transmit signals between cells. Innate immune cells include eosinophils, neutrophils, basophils, macrophages, dendritic cells, and NK (natural killer) cells.

[0023] On the other hand, adaptive immunity is an immunity that remembers pathogens in the body and can effectively eliminate them when encountered again. It takes longer to respond than innate immunity, but has the diversity to react to a variety of pathogens. Adaptive immune cells include B cells and T cells, and T cells are further subdivided into helper T cells, killer T cells, and regulatory T cells. B cells change into plasma cells or memory B cells depending on the condition.

[0024] Furthermore, there are NKT cells, which activate both innate and adaptive immunity. Of the aforementioned immune cells, the cells on which this dendritic cell preparation acts directly are NKT cells, but the adjuvant effect of IFN-γ, which is produced by the activation of NKT cells, also activates NK cells, dendritic cells, T cells (helper T cells, killer T cells), B cells, and other cells.

[0025] Below, we will briefly explain the immune cells and substances related to immune function that are involved in the action of the dendritic cell preparation produced by this method for producing a dendritic cell preparation.

[0026] <Terminology for immune cells and substances related to immune function> <Terminology: Antigen> A foreign substance that enters the body and serves as a marker for adaptive immune cells to recognize as a target for attack. In the case of cancer antigens, immune cells recognize them as targets for attack based on the protein structure that does not exist in normal cells.

[0027] <Terminology: Antibody> A general term for proteins called immunoglobulins, cancer antibodies bind to cancer antigens on cancer cells and attack them through the following three actions. Neutralizing effect: Prevents cancer cell proliferation ADCC activity: Acts as a marker for killer T cells and NK cells, assisting them in attacking cancer CDC activity: Complements (a type of protein synthesized in the body and present in serum; a substance involved in immune responses such as infection prevention; there are nine types, C1 to C9) bind to antibodies that have bound to cancer antigens on cancer cells, activating complements C1 to C9 in a chain reaction, which then opens holes in the cell membrane of the cancer cells, damaging and killing them.

[0028] <Terminology: Cytokine> A general term for proteins secreted by immune cells and physiologically active substances involved in intercellular interactions. They transmit signals to target cells, causing various cellular responses such as cell activation, cell proliferation, differentiation, cell death, and functional expression. Interleukins, interferons, and tumor necrosis factors are types of cytokines.

[0029] <Terminology: Cytokine: Interleukin> More than 30 types of interleukins, a type of cytokine, have been identified to date. They are secreted in large quantities by lymphocytes, a type of white blood cell that fights foreign substances in the body, and phagocytes such as macrophages and neutrophils. Interleukins are referred to by numerical names such as interleukin-2 (hereinafter, interleukins will be abbreviated as IL. For example, interleukin-4 is IL-4). For example, the sources of production and functions of some interleukins are described below.

[0030] <Terminology: Cytokine, Interleukin, IL-4> IL-4 is one of the Th2 cytokines, and is produced by activated type 2 helper T cells (Th2 cells) and NKT cells. It promotes the proliferation and differentiation of antigen-presenting cells. It affects B cells, T cells, macrophages, monocytes, etc. Naive T cells differentiate into Th2 cells in response to stimulation by cytokines such as IL-4 and IL-13. When IL-4 acts on activated B cells, a class switch occurs in which the immunoglobulins (antibodies) produced change from IgM to IgE and IgG1. In this way, it is involved in the humoral immune system. NKT cells are activated when they recognize α-galactosylceramide presented by antigen-presenting cells (dendritic cells), and produce IL-4 and IFN-γ.

[0031] <Terminology: Cytokine, Interleukin, IL-12> IL-12 is produced by phagocytes (cells that migrate between tissues in animals and are responsible for cellular immunity, such as macrophages, monocytes, and neutrophils) and dendritic cells. It is an NK cell stimulating factor, and together with IFN-γ, it acts on naive T cells to differentiate them into Th1 cells, a type of helper T cell. Th1 cells produce Th1 cytokines such as IFN-γ and are involved in cellular immunity, activating macrophages and killer T cells. α-Galactosylceramide causes dendritic cells (antigen-presenting cells) to produce IL-12. IL-12 produced by antigen-presenting cells acts on NKT cells to produce IFN-γ and, via the Fas ligand on the surface of NKT cells, causes cytotoxic activity against target cells expressing the Fas antigen (Fas receptor).

[0032] <Terminology: Cytokine, Interferon> Interferon, a type of cytokine, activates NK cells and macrophages, which attack cancer cells and virus-infected cells, and has the function of suppressing the growth of viruses and tumor cells and promoting the phagocytosis of cancer cells (adjuvant action). It has also been approved by the government as an antiviral drug and anticancer agent, and is used in the treatment of multiple myeloma, brain tumors, and kidney cancer.

[0033] <Terminology: Cytokine, Interferon, IFN-γ> IFN-γ is an important cytokine in both the innate and adaptive immune systems. IFN-γ is produced primarily by NK cells and NKT cells as part of the innate immune response, and after the induction of antigen-specific immunity, it is produced by Th1 cells, killer T cells, macrophages, etc. It accelerates the processing of large amounts of invading non-self antigens and enhances the cellular immune response. It is an important activator of macrophages, stimulating them to phagocytose and kill bacteria. It promotes NK cell activity and differentiates naive T cells into Th1 cells.

[0034] <Terminology: Cytokine: Tumor Necrosis Factor> Tumor necrosis factor (TNF) is a substance secreted by cells such as lymphocytes that causes tumor cells to necrotize. In addition to acting on most malignant cells, it also promotes immune function. In a narrow sense, there are three types: TNF-α, TNF-β (lymphotoxin (LT)-α), and LT-β.

[0035] <Terminology: Cytokine: Tumor necrosis factor: TNF-α> TNF-α is mainly produced by macrophages and was discovered as a cytokine that causes hemorrhagic necrosis in solid cancers. Generally, when people talk about tumor necrosis factor, they are referring to TNF-α. It is involved in the expression of cell adhesion molecules and the induction of apoptosis. Apoptosis means controlled and regulated cell suicide, or programmed cell death.

[0036] <Terminology: NK cells> NK cells have various receptors that capture abnormal cells, and when they discover cells that differ from the normal cells that make up the human body, such as virus-infected cells or cancer cells (they remember the cells that make up the human body), they recognize them as abnormal and have the ability to damage the abnormal cells.

[0037] <Terminology: Dendritic cells> Antigen-presenting cells. They acquire the ability to present antigens specific to foreign substances by ingesting (phagocytosis) them (such as pathogenic bacteria, virus-infected cells, or cancer cells), or by receiving antigens from macrophages, etc. They then have the role of presenting these antigens to T cells, causing them to be recognized as targets for attack. Dendritic cells have the phagocytic ability to ingest viruses and cancer cells, thereby acquiring antigens and gaining the ability to present them to other immune cells. Early dendritic cells (immature dendritic cells) have the ability to ingest antigens (phagocytosis), but are unable to activate naive T cells (they can be said to lack antigen-presenting ability). Mature dendritic cells acquire the antigen-presenting ability to activate T cells through maturation, but have lost the ability to ingest antigens (phagocytosis).

[0038] <Terminology: Helper T cells> When an antigen is presented to them by dendritic cells, they recognize it as a target for attack and instruct killer T cells to attack. They also produce cytokines to activate B cells. Furthermore, when an antigen is presented to them by B cells, they determine whether the antigen is a dangerous foreign substance and convey the result to the B cells. They also have the function of assisting in antibody production.

[0039] <Terminology: Killer T Cells> Killer T cells recognize antigens presented by MHC class I molecules (MHC class I molecules primarily bind peptides generated by the degradation of cytoplasmic proteins by the proteasome (a protein-degrading enzyme complex) (as a marker identifying the human self). The MHC I-peptide complex is then inserted into the outside of the cell membrane via the endoplasmic reticulum membrane. Epitope peptides bind to the extracellular portion of the MHC I-peptide molecule. In this way, the MHC I-peptide molecule presents intracellular proteins to killer T cells. However, MHC I-peptide molecules can also present peptides formed from foreign proteins, a process known as cross-presentation), recognize self and non-self, and destroy non-self cells. The ability to recognize self and non-self is conferred by competence education (negative selection) in the thymus, and this ability is utilized by MHC I-peptide molecules. Thus, the T cell response, which is adaptive immunity, begins with antigen presentation of antigen peptides by MHC molecules. Under the direction of helper T cells, killer T cells kill and eliminate cells that are dangerous or unnecessary to the body, such as virus-infected cells and cancer cells.

[0040] <Terminology: B cells> Stimulated by cytokines produced by helper T cells, B cells produce antibodies. Even if the antigen is eliminated, they become memory B cells and remember the antigen, preparing for the next invasion.

[0041] <Terminology: NKT cells> These are cells that have the characteristics of both T cells and NK cells. When activated, they produce cytokines (IFN-γ) and also have the function of inducing responses to immunostimulatory and suppressive therapy. The most anticipated effect of the formulation of this invention is its adjuvant action, which activates various immune cells in the body and, importantly, promotes their proliferation.

[0042] <Effects of dendritic cell preparations that stimulate NKT cells> The main effects expected from activating NKT cells with this preparation include both non-specific and specific immune effects, such as promoting the maturation of dendritic cells, adjuvant effects (activation and proliferation of various immune cells), inducing apoptosis in cancer cells, and inhibiting angiogenesis. Apoptosis refers to the controlled and regulated suicide of cells, i.e., programmed cell death.

[0043] As described above, by using NKT cell-stimulating dendritic cell preparations that activate the innate immune system, various immune functions in the body can be activated to attack cancer cells.

[0044] The embodiments will be described in detail below, but the substances used during the manufacturing method are common to all embodiments. Manufacturers and the like will be listed only when they are first mentioned.

[0045] <Embodiment 1: Overview> Mainly, claim 1 is a manufacturing method for converting monocytes collected from a beneficiary (apheresis or collected monocytes, or peripheral blood containing monocytes) into dendritic cells that stimulate NKT cells, and producing a dendritic cell preparation.

[0046] Hereinafter, in this specification, the term "beneficiary" refers to a person who wishes to benefit from the effects of administering a dendritic cell preparation for one or more of the following purposes: cancer treatment, cancer prevention, and immune enhancement, and who provides their own monocytes, which are the raw material for the preparation.

[0047] <Embodiment 1: Production Method> First, an outline of the method for producing an NKT cell-stimulating dendritic cell preparation of the present invention will be described. Next, the action of this preparation will be described below.

[0048] <Embodiment 1: (1) Adhesion Process: Preparation of Monocytes> Monocytes collected from a recipient (monocytes collected by component collection or blood collection, or peripheral blood containing monocytes) are prepared. "Preparation" refers to the delivery of monocytes collected from a recipient (monocytes collected by component collection or blood collection, or peripheral blood containing monocytes) to a manufacturing site, but does not include the blood collection itself. In this adhesion process, preparation may also include the delivery of culture vessels and liquid media to be used later to the manufacturing site and preparing them for use. Unless otherwise specified, in this specification, a "culture vessel" refers to a culture vessel that contains a culture medium such as a liquid medium.

[0049] "Component collection" refers to the process of withdrawing blood from the body, separating the desired blood components and factors from the blood using specialized equipment, and then returning the blood to the body. In the present invention, peripheral blood mononuclear cells, including monocytes, are separated as blood components, and approximately 100 cc of blood components are collected. The blood components obtained after the separation of the monocyte-containing peripheral blood mononuclear cells contain plasma and platelets in addition to the desired blood components. Component collection places a significant burden on the body, as an anticoagulant is mixed into the blood before the separation of the monocyte-containing peripheral blood mononuclear cells to prevent blood clotting, and the anticoagulant is then returned to the body. Furthermore, the process of collecting the components to separate the monocyte-containing peripheral blood mononuclear cells requires a long time.

[0050] It is also possible to collect 100 to 400 mL of peripheral blood instead of collecting apheresis. Although apheresis contains a higher proportion of monocytes, peripheral blood collection is acceptable because it can be collected in a short time without using an anticoagulant.

[0051] <Embodiment 1: (1) Adhesion Step: Settling> Next, mononuclear cells are collected from the collected peripheral blood mononuclear cells, including monocytes, by density centrifugation using Ficoll (registered trademark). (Ficoll (registered trademark) is a part of Ficoll-Paque (registered trademark) and is used to separate blood into its components (e.g., red blood cells, white blood cells, etc.).) The collected mononuclear cells are placed in a culture vessel containing a liquid medium. It is desirable to place the mononuclear cells collected from the recipient into a culture vessel containing a medium (preferably a liquid medium) within approximately 72 hours of collection. The start of culture is the time when the mononuclear cells containing monocytes are placed into a culture vessel containing a medium (preferably a liquid medium). Unless otherwise specified, the term "monocytes are placed into a culture vessel" hereinafter refers to the placement of the mononuclear cells into a culture vessel containing a medium (preferably a liquid medium). The mixture is then left to stand for approximately 30 minutes in a sterilized, constant-temperature environment at 37°C for incubation. Unless otherwise specified, steps following the settling are performed in a sterilized, constant-temperature environment at 37°C. The time for standing may be longer than 30 minutes, but if it is shorter than 30 minutes, a sufficient number of monocytes will not adhere to the inner surface of the container, so it is preferable to stand for at least about 30 minutes.

[0052] As used herein, "adhesion" to the inner surface of a culture vessel does not mean intentionally pressing cells against the inner surface of the culture vessel or using some kind of substance to act as an adhesive and attach the cells so that they cannot easily separate from the inner surface of the culture vessel. "Adhesion" refers to the state in which cells come into contact with the inner surface and then maintain that contact without the application of external forces other than gravity.

[0053] <Embodiment 1: (2) Non-adherent cell removal step: removal of non-adherent cells> After the above-described standing (e.g., standing for 30 minutes), non-adherent cells including monocytes that do not adhere to the inner surface of the culture vessel and are floating in the liquid medium are removed (transferred to another vessel). Cells that adhere to the inner wall surface of the vessel (monocyte fraction) remain in the culture vessel containing the liquid medium.

[0054] The removed non-adherent cells, including monocytes, are preferably cultured separately or cryopreserved. The removed non-adherent cells (including NKT cells) can be used to verify the efficacy of the preparation by co-culturing them with the prepared preparation. After removing the non-adherent cells, a detachment step may be performed in which cells adhered to the inner wall of the container (monocyte fraction) are detached and suspended in a liquid medium. During the above-mentioned standing, monocytes mainly adhere to the inner wall of the container, and after detachment, mainly monocytes float in the liquid medium.

[0055] <Embodiment 1: (3) Differentiation Step: Differentiation of Monocytes into Immature Dendritic Cells> To a culture vessel containing the liquid medium from which non-adherent cells have been removed, are added predetermined factors for differentiating monocytes into immature dendritic cells: 50 ng / mL of granulocyte-macrophage colony-stimulating factor (hereinafter referred to as GM-CSF) (preferably approximately 30 ng / mL to 70 ng / mL; if the concentration is less than this, the stimulation is too weak and differentiation becomes slow, and if the concentration is higher, the differentiation rate will plateau, which is unreasonable from a cost perspective), and 50 ng / mL of interleukin-4 (hereinafter referred to as IL-4) (preferably approximately 30 ng / mL to 70 ng / mL; if the concentration is lower than this, the stimulation is too weak and differentiation becomes slow, and if the concentration is higher, the differentiation rate will plateau, which is unreasonable from a cost perspective). After addition, the culture is continued. By stimulating monocytes with the addition of GM-CSF and IL-4, the monocytes in culture differentiate into immature dendritic cells. The substances used to stimulate differentiation are preferably, but not limited to, the above-mentioned GM-CSF and IL-4. The addition of the stimulating substances results in a state in which immature dendritic cells are present in much greater numbers (predominantly present) than undifferentiated monocytes or mature dendritic cells within the culture vessel. The differentiated immature dendritic cells account for the majority of the cells within the culture vessel, preferably 80% or more, and more preferably 90% or more.

[0056] <Embodiment 1: (4) Pulse Step: Pulsing with α-Galactosylceramide> As described above, α-Galactosylceramide is pulsed into a liquid medium in a culture vessel containing a majority of immature dendritic cells. The α-Galactosylceramide used was KRN7000, manufactured by Kyowa Kirin Co., Ltd. By pulsing with α-Galactosylceramide, immature dendritic cells become immature dendritic cells capable of stimulating NKT cells after maturation. α-Galactosylceramide is a glycolipid antigen necessary for activating NKT cells. A feature of the present invention is that α-Galactosylceramide is directly imparted to immature dendritic cells. While mature dendritic cells generally acquire the antigen-presenting ability of α-Galactosylceramide through the phagocytosis of various foreign substances, the present invention is characterized in that α-Galactosylceramide is imparted (pulsed) to dendritic cells at an immature stage, thereby imparting antigen-presenting ability to mature dendritic cells. The inventors of the present application have confirmed that, although prior art Patent Document 1 describes that pulsing mature dendritic cells with α-galactosylceramide imparts antigen presentation ability, according to the present invention, pulsing at least immature dendritic cells is more effective in presenting antigens to and activating NKT cells.

[0057] <Embodiment 1: (5) NKT-stimulated dendritic cell induction step: dendritic cell maturation> After pulsing with α-galactosylceramide as described above, GM-CSF (5 ng / mL; preferably about 3 ng / mL to 7 ng / mL. If the concentration is less than this, the stimulation is too weak and maturation is slow, and even if the concentration is higher, the maturation rate will plateau and it is unreasonable from a cost perspective) and IL-4 (5 ng / mL; preferably about 3 ng / mL to 7 ng / mL. If the concentration is lower than this, the stimulation is too weak and maturation is slow, and even if the concentration is higher, the maturation rate will plateau and it is unreasonable from a cost perspective) are added. and OK-432 (10 ng / mL: approximately 7 ng / mL to 13 ng / mL is preferable. Less than this concentration will be too weak, slowing maturation, while more than this concentration will cause the maturation rate to plateau, making it unreasonable from a cost perspective), and PGE2 (50 ng / mL: approximately 30 ng / mL to 70 ng / mL is preferable. Less than this concentration will be too weak, slowing maturation, while more than this concentration will cause the maturation rate to plateau, making it unreasonable from a cost perspective) are added to the liquid medium in the culture vessel. These four ingredients should be added on the sixth day after the start of culture. Immature dendritic cells mature into mature dendritic cells upon stimulation by the added ingredients. OK-432 is the trade name Picibanil, manufactured by Chugai Pharmaceutical Co., Ltd., and PGE2 is prostaglandin E2 (hereinafter referred to as PGE2). The substances used to stimulate maturation are preferably, but not limited to, the above-mentioned GM-CSF, IL-4, OK-432 and PGE2.

[0058] <Embodiment 1: (5) NKT-stimulated dendritic cell induction step: final test> After the mature dendritic cells are obtained, a sterility test, an endotoxin test, and a mycoplasma test are performed to confirm whether they are safe to inject into humans. Furthermore, surface marker measurements are performed to evaluate the quality of the dendritic cells. These quality confirmation tests may be supplemented with other tests as appropriate. Furthermore, if the administration to the beneficiary is not to be performed immediately or if the administration is planned to be divided into several doses, the produced dendritic cells may be collected as needed and cryopreserved in a cryopreservation solution to freeze the cells. 7 0.5 x 10 or more / ml / vial (0.5 x 10 when using whole blood as raw material) 6The dendritic cell preparation is prepared to a concentration of 100 or more cells / ml / vial and then frozen and stored under liquid nitrogen. A vial is a type of container for injections, and is classified as a sealed container in the Japanese Pharmacopoeia. To achieve the desired effect, it is preferable to use a concentration equal to or higher than the above. This completes the method for producing the dendritic cell preparation of the present invention that stimulates NKT cells.

[0059] <Embodiment 1: Effect of a dendritic cell preparation that stimulates NKT cells> When the dendritic cell preparation of the present invention that stimulates NKT cells is administered to a recipient from whom blood has been drawn, the preparation of the present invention stimulates and activates Vα24-NKT cells in the recipient's body, causing them to produce IFN-γ, a type of cytokine, resulting in an adjuvant effect. NK cells are strongly activated by this adjuvant effect and attack cancer cells or cells other than normal cells through a cytotoxic response. Activated NKT cells also activate the adaptive immune system by promoting the maturation of immature dendritic cells in the body. Activating both the innate and adaptive immune systems is effective not only in cancer treatment, but also in cancer prevention and disease prevention by improving the immune system of healthy individuals.

[0060] Next, the effects of the NKT cell-stimulating dendritic cell preparation of the present invention when it is returned to the body of a recipient from whom monocytes have been collected to produce said preparation will be described.

[0061] <Embodiment 1: Action of the Present Preparation: Return to the Body by Intravenous Infusion> The present preparation, which contains immature dendritic cells pulsed with α-galactosylceramide and then matured dendritic cells, is returned to the body of a recipient by a method such as intravenous infusion.

[0062] <Embodiment 1: Effect of the present formulation: activation of Vα24-NKT cells> Dendritic cells containing the formulation of the present invention pass through blood vessels in the body and bind the ingested glycolipid antigen α-galactosylceramide to a ligand called CD1d, presenting it to Vα24-NKT cells in the body. Vα24-NKT cells in the body are activated when α-galactosylceramide binds to their receptors (resulting in antigen presentation).

[0063] <Embodiment 1: Effect of the present formulation: activated NKT cells: TNF-α production, angiogenesis inhibition> Activated Vα24-NKT cells produce TNF-α (tumor necrosis factor-α) and stimulate immature dendritic cells (immature DCs). At the same time, TNF-α inhibits angiogenesis in cancer cells.

[0064] <Embodiment 1: Effect of the present formulation: Maturation of dendritic cells and activation of the adaptive immune system> Immature dendritic cells phagocytose neoantigens, which are cancer antigens released by cancer cells or dead cancer cells. Alternatively, immature dendritic cells stimulated by TNF-α from activated Vα24-NKT cells phagocytose neoantigens. Dendritic cells that have phagocytosed neoantigens mature, also due to the stimulating effect of TNF-α. Killer T cells and helper T cells receive antigen presentation from matured dendritic cells as a stimulus. The helper T cells that have received the antigen presentation stimulate B cells with cytokines. The stimulated B cells produce and release cancer cell-specific antibodies.

[0065] <Embodiment 1: Effect of the Present Preparation: Apoptosis, Cytotoxic Activity> NK cells are activated by stimulation with IFN-γ produced by activated Vα24-NKT cells. The activated NK cells and activated Vα24-NKT cells then attack cancer cells (or pathogens) that are not the recipient's own cells, killing them (cytotoxic activity) or promoting apoptosis (innate immune system). Meanwhile, antibodies released from the B cells bind to cancer cells. Killer T cells attack by creating holes in the cell membrane of antibody-bound cancer cells (or pathogens), causing necrosis (cytotoxic activity), or by producing substances such as TNF-β (tumor necrosis factor, a type of cytokine) to promote apoptosis (adaptive immune system). Attacks from activated NK cells and activated Vα24-NKT cells (natural immune system) occur 1 to 2 days after intravenous infusion of this preparation, but attacks from killer T cells (adaptive immune system) occur after antigen presentation from dendritic cells, and therefore take time, about 7 to 14 days later.

[0066] Killer T cells and helper T cells that attack cancer cells cannot survive for long periods of time, but some of these T cells exist in lymph nodes and other locations as memory killer T cells and memory helper T cells (they are thought to be maintained through replication and replacement of memory T cells). Even after cancer cells have disappeared, if cancer cells that express the same antigen reappear, the memory helper T cells will immediately issue instructions to immune cells to attack because they retain their memory of the previous attack, allowing the killer T cells to respond quickly. In addition to T cells, B cells that have released antibodies also exist as memory B cells, and can quickly release antibodies in the event of a recurrence.

[0067] <Effects> By producing dendritic cells that stimulate NKT cells, when they are returned to the recipient's body, it is expected that NK cells will be activated through the innate immune system pathway, and by stimulating dendritic cells, helper T cells, killer T cells, and B cells will be indirectly activated. By improving overall immunity rather than just targeting specific cancers, it is expected that beneficiaries weakened by cancer will be prevented from contracting diseases other than cancer, and even if they do contract them, they will be less severe and recover more quickly. In addition to cancer treatment, it is also effective in preventing cancer and other diseases by improving immunity. Furthermore, because this dendritic cell preparation is cultured from the recipient's own cells and is made exclusively for the recipient, it is a highly safe preparation with no rejection reactions.

[0068] <Embodiment 2: Overview> Mainly Claim 2 In this embodiment 2, based on the method for producing a dendritic cell preparation of embodiment 1, the pulse step (4) is performed on the third or fourth day, with the day on which a specific factor is added in the differentiation step (3) being considered as day 0.

[0069] <Embodiment 2: (4) Pulse Step: Pulse of α-galactosylceramide> In this embodiment 2, the timing of α-galactosylceramide pulsing is earlier than in embodiment 1, and α-galactosylceramide is pulsed into the liquid medium in a culture vessel containing a predominance of immature dendritic cells on either day 3 or day 4, with the day on which GM-CSF and IL-4 were added as predetermined factors in the differentiation step being considered day 0. As in embodiment 1, α-galactosylceramide used was KRN7000 manufactured by Kyowa Kirin Co., Ltd.

[0070] <Embodiment 2: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the production method of the present invention are expected to stimulate and activate Vα24-NKT cells, thereby producing cytokines such as IFN-γ and activating various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, NKT cells, etc.)) removed in the non-adherent cell removal step (2) of the production method and separately cultured and stored are added to the preparation of the present invention after completion of the preparation, and co-culture is performed to investigate the ratio of the number of IFN-γ-producing NKT cells to the total number of lymphocytes. The relationship between the pulse timing and the ratio of NKT cells after the co-culture is investigated, and the optimal pulse timing is determined. The pulse timing was determined in this manner. The use of non-adherent cells is intended to avoid placing a physical burden on the recipient, and has no other intention. Therefore, peripheral blood may be newly drawn from the beneficiary and the dendritic cell preparation produced by the production method of the present invention may be added to the drawn peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes. This observation revealed that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulating dendritic cell induction step," it could also be said to be an "NKT proliferation-stimulating dendritic cell induction step."

[0071] In this embodiment, the day on which specific factors (e.g., GM-CSF and IL-4) were added to differentiate monocytes into immature dendritic cells is designated as day 0, and time is expressed in days hereafter. After the formulation was completed, non-adherent cells were added and co-cultured to confirm the efficacy of the formulation. To verify the optimal pulse timing, collected monocytes were divided into thirds, and three samples of dendritic cell formulations with different α-galactosylceramide pulse timings were prepared. Each sample was pulsed with α-galactosylceramide (concentration: 100 ng / mL) on day 2 (48 hours) after the addition of the specific factors (condition 1), on day 4 (96 hours) (condition 2), and on day 5 (120 hours) (condition 3).

[0072] To confirm the effectiveness of this preparation, non-adherent cells were added and co-culture was initiated on day 6, with the day on which a specific factor was added to induce monocytes to become immature dendritic cells being designated day 0. The ratio of NKT cell counts to lymphocyte counts was investigated three times: on the day co-culture began (day 0 from the start of co-culture), on day 7 from the start of co-culture, and on day 14 from the start of co-culture.

[0073] Figure 1 shows the results of the α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. These results were obtained using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Furthermore, among the three conditions, the NKT cell ratio (%) after co-culture was highest when pulsing was performed on day 4, where day 0 is the day when a specific factor was added to differentiate monocytes into immature dendritic cells. Figure 2a shows the scatter plot of the relationship between the maximum NKT cell ratio (%) on day 7 after co-culture and the pulse timing (day), where day 0 is the day when the specific factor was added. Figure 2a also shows the approximate curve, extrapolated both forward and backward, based on a quadratic fit. The coefficient of determination for this approximate curve is 1, which is considered sufficient for reference. The peak of the curve is between the third and fourth days of the pulse timing (3.7 days when calculated using the approximation formula). The preferred range is approximately 2.5 to 5 days, which corresponds to -10% of the peak value. Because the lifespan of dendritic cells is approximately several days to one week, the production process using this method (from monocyte collection or the addition of specific factors to differentiate monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells) takes too long (note that the subsequent time required for complete maturation is approximately 10 to 20 hours, and therefore this time period may also be included). In this experiment, the timing of the α-galactosylceramide pulse differed between Conditions 1 and 3, but GM-CSF, IL-4, OK-432, and PGE2 were added simultaneously) shortened the period during which the product could be used. Therefore, taking into consideration the need to complete the preparation within one week from the start of culture, it is more preferable to pulse between days 3 and 4.5, which is also the range where the concentration is down to -5% of the peak value, and it is better to pulse on day 3 or 4. Most preferably, the pulse is performed on day 4.

[0074] When α-galactosylceramide is pulsed into immature dendritic cells, the preparation can be maximized in the recipient's body by pulsing it either on the third or fourth day after adding certain factors (e.g., GM-CSF and IL-4) to differentiate monocytes into immature dendritic cells.

[0075] <Embodiment 3: Overview> Mainly Claim 3 In this embodiment 3, based on the method for producing a dendritic cell preparation of embodiment 1, the (4) pulse step is carried out between 60 and 108 hours after the addition of a predetermined factor in the (3) differentiation step.

[0076] <Embodiment 3: (4) Pulse Step: Pulse of α-galactosylceramide> In this embodiment 3, the timing of α-galactosylceramide pulse is earlier than that in embodiment 1, and α-galactosylceramide is pulsed between 60 and 108 hours after the addition of GM-CSF and IL-4 as predetermined factors in the differentiation step. As in embodiment 1, α-galactosylceramide was used, model name KRN7000 manufactured by Kyowa Kirin Co., Ltd.

[0077] <Embodiment 3: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the manufacturing method of the present invention are expected to stimulate and activate Vα24-NKT cells, thereby producing cytokines such as IFN-γ and activating various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, etc.)) removed in the non-adherent cell removal step (2) of the manufacturing method are added to the completed preparation after co-culture, and the proportion of NKT cells producing IFN-γ is investigated. The relationship between the pulse timing and the proportion of NKT cells after co-culture is investigated, and the optimal pulse timing is determined in the same manner as in Embodiment 2. The pulse timing was determined in this manner. Note that non-adherent cells are used solely to avoid imposing a physical burden on the recipient, and no other purpose is intended. Therefore, peripheral blood may be newly collected from the recipient, and the dendritic cell preparation produced by the manufacturing method of the present invention may be added to the collected peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes, and what became clear from this observation was that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulated dendritic cell induction step," it can also be said as an "NKT proliferation-stimulated dendritic cell induction step."

[0078] In this embodiment, the time when a specific factor (e.g., GM-CSF and IL-4) was added to differentiate monocytes into immature dendritic cells was defined as time 0, and time is expressed in units of hours hereafter. After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse timing, blood-collected monocytes were divided into thirds using a production method based on the production method of Embodiment 1, and three types of dendritic cell preparation samples were prepared, differing only in the timing of α-galactosylceramide pulse. Each sample was pulsed with α-galactosylceramide (concentration: 100 ng / mL) 48 hours (day 2) after the addition of the specific factor (condition 1), 96 hours (day 4) (condition 2), and 120 hours (day 5) (condition 3).

[0079] To confirm the effectiveness of this formulation, non-adherent cells were added 144 hours (day 6) after the addition of a specific factor to induce monocytes to become immature dendritic cells, and co-culture was initiated. The ratio of NKT cell counts to lymphocyte counts was investigated three times: on the day of the start of co-culture (day 0 from the start of co-culture), on day 7 from the start of co-culture, and on day 14 from the start of co-culture.

[0080] Figure 1 shows the results of the α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. These results were obtained using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Furthermore, among the three conditions, the NKT cell ratio (%) was highest when the pulse was administered 96 hours (day 4) after the addition of a specific factor to differentiate monocytes into immature dendritic cells. The relationship between the maximum NKT cell ratio (%) on day 7 after co-culture and the pulse timing is shown in the scatter plot in Figure 2b. Figure 2b also shows the approximate curve, extrapolated both before and after the quadratic fit. The coefficient of determination for this approximate curve is 1, which is considered sufficient for reference. The peak of the curve is between 70 and 96 hours after the pulse timing (90 hours calculated from the approximate equation).

[0081] The preferred range is approximately 60 to 118 hours after the treatment, which is 10% below the peak value. Because the lifespan of dendritic cells is approximately several days to one week (up to 168 hours), if the production process using this method (from collection of monocytes or addition of a specific factor for differentiating monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the period from addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells (note that the subsequent time required for complete maturation is approximately 10 to 20 hours, and therefore steps corresponding to this time may also be included) takes too long. In this experiment, the timing of the α-galactosylceramide pulse differed between Conditions 1 and 3, but GM-CSF, IL-4, OK-432, and PGE2 were added simultaneously) takes too long, resulting in a shortened usable period for the formulation. Therefore, in consideration of completing the preparation within one week from the start of culture, pulsing is preferably performed between 60 and 108 hours after the start of culture, and more preferably between 70 and 108 hours, which is the range where the peak value is -5%.

[0082] When α-galactosylceramide is pulsed into immature dendritic cells, the preparation can be made to exert its maximum effect in the recipient's body by pulsing the cells between 60 and 108 hours after adding certain factors (e.g., GM-CSF and IL-4) to differentiate monocytes into immature dendritic cells.

[0083] <Embodiment 4: Overview> Mainly Claim 4 In this embodiment 4, based on the manufacturing method of the dendritic cell preparation of embodiment 1, the (4) pulsing step is carried out by the fourth or fifth day, with the day on which the monocytes collected from the recipient in the adhesion step (1) are placed in the culture vessel being considered as day 0.

[0084] <Embodiment 4: (4) Pulse Step: Pulse of α-galactosylceramide> In this embodiment 4, the timing of pulsing α-galactosylceramide is earlier than in embodiment 1, and α-galactosylceramide is pulsed between day 4 and day 5, with the day on which monocytes collected from the recipient are placed in a culture vessel being day 0. As in embodiment 1, α-galactosylceramide used was Kyowa Kirin Co., Ltd., model name KRN7000.

[0085] <Embodiment 4: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the production method of the present invention are expected to stimulate and activate Vα24-NKT cells, produce IFN-γ, and activate various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, etc.)) removed in the non-adherent cell removal step (2) of the production method are added to the completed preparation, followed by co-culture, and the ratio of NKT cells producing IFN-γ is investigated. The relationship between the pulse timing and the ratio of NKT cells after co-culture is investigated, and the optimal pulse timing is determined. The pulse timing was determined in this manner. Note that non-adherent cells are used solely to avoid imposing a physical burden on the recipient, with no other intention. Therefore, peripheral blood may be newly collected from the recipient, and the dendritic cell preparation produced by the production method of the present invention may be added to the collected peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes, and what became clear from this observation was that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulated dendritic cell induction step," it can also be said as an "NKT proliferation-stimulated dendritic cell induction step."

[0086] In this embodiment, the time is expressed in days, starting from the time when monocytes collected from the recipient were placed in a culture vessel and culture was initiated. After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse timing, blood-collected monocytes were divided into three parts using a manufacturing method based on the manufacturing method of Embodiment 1, and three types of dendritic cell preparation samples were prepared, differing only in the timing of α-galactosylceramide pulse. The monocytes collected from the recipient were pulsed with α-galactosylceramide (concentration: 100 ng / mL) three days (72 hours) after being placed in the culture vessel (Condition 1), five days (120 hours) after being placed in the culture vessel (Condition 2), and six days (144 hours) after being pulsed (Condition 3). In this experiment, GM-CSF and IL-4 were added as predetermined factors for differentiating monocytes into immature dendritic cells 24 hours after placing the monocytes collected from the recipient in the culture vessel.

[0087] To confirm the effectiveness of this formulation, the day that monocytes collected from the recipients were placed in the culture vessel was set as day 0, and non-adherent cells were added on day 7 to begin co-culture. The ratio of NKT cell counts to lymphocyte counts was investigated three times: on the day that co-culture began (day 0 from the start of co-culture), day 7 from the start of co-culture, and day 14 from the start of co-culture.

[0088] Figure 3 shows the results of the α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. These results were obtained using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Furthermore, among the three conditions, the NKT cell ratio (%) was highest when pulsed on day 5 after the start of culture. The relationship between the maximum NKT cell ratio (%) on day 7 after co-culture and the pulse timing is shown in the scatter plot in Figure 4a. Figure 4a also shows the approximate curve, extrapolated forward and backward, based on a quadratic approximation. The coefficient of determination for this approximate curve is 1, which is considered sufficient for reference. The peak of the curve is between days 4 and 5, with day 0 being considered as day 0 (4.7 days calculated from the approximation formula). The preferred range is approximately days 3.5 to 6, which is up to -10% of the peak value. Since the lifespan of dendritic cells is approximately several days to one week, if production by this production method (from monocyte collection or addition of a specific factor for differentiating monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the period from addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells (note that, since the time required for complete maturation thereafter is approximately 10 to 20 hours, steps corresponding to this time may also be included) takes too long, the usable period of the formulation will be shortened. Therefore, considering that the formulation should be completed within one week from the start of culture, the preferred range is between days 3.9 and 5.5, which is also the range where the peak is -5%. Pulsing on day 5 is the most preferable.

[0089] When α-galactosylceramide is pulsed onto immature dendritic cells, the day on which monocytes collected from the recipient are placed in a culture vessel is counted as day 0, and pulsing on day 4 or 5 allows the manufactured preparation to exert its maximum effect within the recipient's body.

[0090] <Embodiment 5: Overview> Mainly Claim 5 In this embodiment 5, based on the method for producing a dendritic cell preparation of embodiment 1, the (4) pulsing step is carried out 84 to 132 hours after the mononuclear cells collected from the recipient in the adhesion step (1) are placed in the culture vessel.

[0091] <Embodiment 5: (4) Pulse Step: Pulse of α-Galactosylceramide> In this embodiment 5, α-Galactosylceramide is pulsed between 84 and 132 hours after monocytes collected from the recipient are placed in a culture vessel, earlier than in embodiment 1. As for α-galactosylceramide, KRN7000 manufactured by Kyowa Kirin Co., Ltd. was used, as in embodiment 1.

[0092] <Embodiment 5: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the production method of the present invention are expected to stimulate and activate Vα24-NKT cells, produce IFN-γ, and activate various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, etc.)) removed in the non-adherent cell removal step (2) of the production method are added to the completed preparation of the present invention, and co-culture is performed to investigate the ratio of NKT cells producing IFN-γ. As in the fourth embodiment, the relationship between the pulse timing and the ratio of NKT cells after the co-culture is investigated, and the optimal pulse timing is determined. The pulse timing was determined in this manner. Note that non-adherent cells are used solely to avoid imposing a physical burden on the recipient, and no other intention is intended. Therefore, peripheral blood may be newly collected from the recipient, and the dendritic cell preparation produced by the production method of the present invention may be added to the collected peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes, and what became clear from this observation was that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulated dendritic cell induction step," it can also be said as an "NKT proliferation-stimulated dendritic cell induction step."

[0093] In this embodiment, the time is expressed as follows, starting from the time when monocytes collected from the recipient were placed in a culture vessel and culture was initiated. After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse timing, a production method based on the production method of Embodiment 1 was used to divide collected monocytes into thirds, and three types of dendritic cell preparation samples were prepared, differing only in the timing of α-galactosylceramide pulse. Each sample was pulsed with α-galactosylceramide (concentration 100 ng / mL) 72 hours (3 days) after the monocytes collected from the recipient were placed in the culture vessel (start of culture) (Condition 1), 120 hours (5 days) after the monocytes were placed in the culture vessel (Condition 2), and 144 hours (6 days) after the monocytes were pulsed (Condition 3). In this experiment, GM-CSF and IL-4 were added as predetermined factors for differentiating monocytes into immature dendritic cells 24 hours after the monocytes collected from the recipient were placed in the culture vessel.

[0094] To confirm the effectiveness of this formulation, mononuclear cells collected from the recipient were placed in a culture vessel, and 168 hours later, non-adherent cells were added to initiate co-culture. The ratio of NKT cells to lymphocytes was investigated three times: on the day co-culture began (day 0), on day 7, and on day 14.

[0095] Figure 3 shows the results of the above-mentioned α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. These results were obtained using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Among the three conditions, this was also obtained using a flow cytometer. The NKT cell ratio (%) on day 7 after the start of co-culture was highest when pulsing was performed on day 5 after the start of co-culture. The relationship between the maximum NKT cell ratio (%) on day 7 after the start of co-culture and the pulse timing is shown in the scatter plot in Figure 4b. Figure 4b also shows the approximate curve obtained by quadratic approximation, extrapolated both before and after the curve. The coefficient of determination for this approximate curve is 1, which is considered sufficient for reference. The peak of the curve is between 96 hours (day 4, assuming that day 0 is the start of culture) and 120 hours (day 5, assuming that day 0 is the start of culture) (approximately 114 hours). The preferred range is approximately 84 hours to 143 hours, which is up to -10% of the peak value. Since the lifespan of dendritic cells is approximately several days to one week (168 hours), if the production process using this production method (from monocyte collection or the addition of a specific factor to differentiate monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the period from the addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells (note that, since the time required for complete maturation thereafter is approximately 10 to 20 hours, steps corresponding to this time may also be included) takes too long, the usable period of the formulation will be shortened. Therefore, in order to complete the formulation within one week from the start of culture, pulsing is preferably performed between 84 and 132 hours. More preferably, pulsing is performed between 94 and 132 hours, which is the range at which the peak is -5% of the peak.

[0096] When α-galactosylceramide is pulsed into immature dendritic cells, the preparation can be made to exert its maximum effect in the recipient's body by pulsing the cells between 84 and 132 hours after the monocytes collected from the recipient are placed in a culture vessel.

[0097] <Embodiment 6: Overview> Mainly Claim 6 In this embodiment 6, based on the method for producing a dendritic cell preparation of embodiment 1, the (4) pulsing step is performed on the fourth or fifth day, with the day on which non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel are removed in the (2) non-adherent cell removal step being set as day 0.

[0098] <Embodiment 6: (4) Pulse step: α-galactosylceramide pulse> In this embodiment 6, the α-galactosylceramide pulse timing is earlier than in embodiment 1, and α-galactosylceramide is pulsed between day 4 and day 5, with the day on which non-adherent cells including monocytes other than cells adhered to the inner surface of the culture vessel are removed in the non-adherent cell removal step (2) being set as day 0. As in embodiment 1, α-galactosylceramide used was model KRN7000 manufactured by Kyowa Kirin Co., Ltd.

[0099] <Embodiment 6: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the production method of the present invention are expected to stimulate and activate Vα24-NKT cells, produce IFN-γ, and activate various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, etc.)) removed in the non-adherent cell removal step (2) of the production method are added to the completed preparation, followed by co-culture, and the ratio of NKT cells producing IFN-γ is investigated. The relationship between the pulse timing and the ratio of NKT cells after the co-culture is investigated, and the optimal pulse timing is determined. The pulse timing was determined in this manner. Note that non-adherent cells are used solely to avoid imposing a physical burden on the recipient, with no other intention. Therefore, peripheral blood may be newly collected from the recipient, and the dendritic cell preparation produced by the production method of the present invention may be added to the collected peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes, and what became clear from this observation was that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulated dendritic cell induction step," it can also be said as an "NKT proliferation-stimulated dendritic cell induction step."

[0100] In this embodiment, the time is expressed in days, starting from the time when non-adherent cells, including monocytes other than those adhered to the inner surface of the culture vessel, were removed in the non-adherent cell removal step (2). After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse timing, blood-collected monocytes were divided into three using a production method based on the production method of Embodiment 1, and three types of dendritic cell preparation samples were prepared, differing only in the timing of α-galactosylceramide pulse. The samples were pulsed with α-galactosylceramide (concentration: 100 ng / mL) three days (72 hours) after removal of non-adherent cells, including monocytes other than those adhered to the inner surface of the culture vessel, in the non-adherent cell removal step (2). (Condition 1) (Condition 2) (Condition 3) (Condition 4) (Condition 5) (Condition 6) (Condition 7) (Condition 8) (Condition 9) (Condition 10) (Condition 11) (Condition 12) (Condition 13) (Condition 14) (Condition 15) (Condition 16) (Condition 17) (Condition 18) (Condition 19) (Condition 20) (Condition 21) (Condition 22) (Condition 23) (Condition 24) (Condition 25) (Condition 26) (Condition 27) (Condition 28) (Condition 29) (Condition 29) (Condition 30) (Condition 31) (Condition 31) (Condition 32) (Condition 33) (Condition 34) (Cond In this experiment, GM-CSF and IL-4 were added as specific factors for differentiating monocytes into immature dendritic cells 24 hours after the removal of non-adherent cells, including monocytes other than those adhered to the inner surface of the culture vessel, in the non-adherent cell removal step (2).

[0101] To confirm the effect of this formulation, the day when non-adherent cells including monocytes other than cells adhered to the inner surface of the culture vessel were removed in the non-adherent cell removal step (2) was set as day 0, and non-adherent cells were added on day 7 to start co-culture. The ratio of the number of NKT cells to the number of lymphocytes was investigated three times: on the day the co-culture started (day 0 from the start of co-culture), on day 7 from the start of co-culture, and on day 14 from the start of co-culture.

[0102] Figure 3 shows the results of the above-mentioned α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. The condition "from the start of culture" on the right side of Figure 3 can be read as "after the removal of non-adherent cells, including monocytes, other than those adhered to the inner surface of the culture vessel in the non-adherent cell removal step (2)." Figure 3 shows the results of an investigation using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Furthermore, among the three conditions, the NKT cell ratio (%) was highest when pulsed on day 5 after removal of non-adherent cells. The relationship between the highest NKT cell ratio (%) on day 7 after co-culture and the pulse timing is shown in the scatter plot in Figure 4a. Figure 4a also shows the approximate curve obtained by quadratic approximation, extrapolated both before and after. The coefficient of determination for this approximate curve is 1, which is considered sufficient for reference. The peak of the curve is between days 4 and 5 (4.7 days calculated from the approximation formula), with the day when non-adherent cells were removed being day 0. The preferred range is approximately days 3.5 to 6, which is up to -10% of the peak value. Since the lifespan of dendritic cells is approximately several days to one week, if production by this production method (from monocyte collection or addition of a specific factor for differentiating monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the period from addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells (note that, since the time required for complete maturation thereafter is approximately 10 to 20 hours, steps corresponding to this time may also be included) takes too long, the usable period of the preparation will be shortened. Therefore, considering that the preparation must be completed within one week after removal of non-adherent cells, the preferred time is between days 3.9 and 5.5, which is also the range where the peak is -5%. Pulsing on day 5 is most preferred.

[0103] When α-galactosylceramide is pulsed onto immature dendritic cells, the preparation can maximize its effectiveness in the recipient's body by pulsing it on the fourth or fifth day, which is the day on which non-adherent cells, including monocytes other than those adhered to the inner surface of the culture vessel, are removed in the non-adherent cell removal step (2).

[0104] <Embodiment 7: Overview> Mainly Claim 7 In this embodiment 7, based on the method for producing a dendritic cell preparation of embodiment 1, the (4) pulsing step is carried out between 84 hours and 132 hours after the removal of non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel in the (2) non-adherent cell removal step.

[0105] <Embodiment 7: (4) Pulse Step: Pulse of α-galactosylceramide> In this embodiment 7, the α-galactosylceramide pulse timing is earlier than in embodiment 1, and α-galactosylceramide is pulsed between 84 and 132 hours after the removal of non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel in the non-adherent cell removal step (2). As in embodiment 1, α-galactosylceramide used was model KRN7000 manufactured by Kyowa Kirin Co., Ltd.

[0106] <Embodiment 7: (4) Pulse Step: Optimal Pulse Timing> Dendritic cell preparations produced by the production method of the present invention are expected to stimulate and activate Vα24-NKT cells, produce IFN-γ, and activate various immune system players. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, etc.)) removed in the non-adherent cell removal step (2) of the production method are added to the completed preparation after co-culture, and the proportion of NKT cells producing IFN-γ is investigated. As in the case of Embodiment 6, the relationship between the pulse timing and the proportion of NKT cells after co-culture is investigated, and the optimal pulse timing is determined. The pulse timing was determined in this manner. Note that non-adherent cells are used solely to avoid imposing a physical burden on the recipient, and no other purpose is intended. Therefore, peripheral blood may be newly collected from the recipient, and the dendritic cell preparation produced by the production method of the present invention may be added to the collected peripheral blood to similarly compare and confirm the effects. Furthermore, co-culture was performed to observe the difference in the increase in the proportion of NKT cells relative to total lymphocytes, and what became clear from this observation was that the proliferation rate of NKT cells (considered to be self-division proliferation) is influenced by the dendritic cell preparation of the present invention. Therefore, although step (5) in claim 1 of the present application is simply described as an "NKT-stimulated dendritic cell induction step," it can also be said as an "NKT proliferation-stimulated dendritic cell induction step."

[0107] In this embodiment, the time is expressed as follows, starting from the time when non-adherent cells, including monocytes, other than those adhered to the inner surface of the culture vessel were removed in the non-adherent cell removal step (2). After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse timing, blood collected monocytes were divided into three using a production method based on the production method of Embodiment 1, and three types of dendritic cell preparation samples were prepared, differing only in the timing of α-galactosylceramide pulse. Each sample was pulsed with α-galactosylceramide (concentration: 100 ng / mL) 72 hours (3 days) after the removal of non-adherent cells (Condition 1), 120 hours (5 days) after the removal of non-adherent cells (Condition 2), and 144 hours (6 days) after the removal of non-adherent cells (Condition 3). In this experiment, GM-CSF and IL-4 were added 24 hours after the removal of non-adherent cells as predetermined factors for differentiating monocytes into immature dendritic cells.

[0108] To confirm the effect of this formulation, non-adherent cells were added 168 hours after their removal, and co-culture was initiated. The ratio of NKT cell counts to lymphocyte counts was investigated three times: on the day the co-culture began (day 0), on day 7, and on day 14.

[0109] Figure 3 shows the results of the above-mentioned α-galactosylceramide pulse timing conditions (conditions 1 to 3) and the ratio of IFN-γ-producing NKT cells (those contained in non-adherent cells) to the total lymphocyte count at each timing after co-culture. The condition "from the start of culture" on the right side of Figure 3 can be read as "after the removal of non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel in the non-adherent cell removal step (2)." Figure 3 shows the results of an investigation using a flow cytometer. Under all three conditions, the ratio of NKT cells to lymphocytes was highest on day 7 after the start of co-culture. Among the three conditions, this was also the result of an investigation using a flow cytometer. The NKT cell ratio (%) on day 7 after the start of co-culture was highest when pulsing was performed on day 5 after the removal of non-adherent cells. The relationship between the maximum NKT cell ratio (%) on day 7 after the start of co-culture and the pulse timing is shown in the scatter plot in Figure 4b. Figure 4b shows the approximate curve obtained by approximating with a quadratic equation, extrapolated before and after the curve. The coefficient of determination of this approximate curve is 1, which is considered to be sufficient for reference. The peak of the curve is between 96 hours (day 4, with day 0 being the day the non-adherent cells were removed) and 120 hours (day 5, with day 0 being the day the non-adherent cells were removed) (approximately 114 hours). The preferred range is approximately 84 to 143 hours, which is up to -10% of the peak value. Since the lifespan of dendritic cells is approximately several days to one week (168 hours), if the production process using this production method (from monocyte collection or the addition of a specific factor to differentiate monocytes into immature dendritic cells to maturation into mature dendritic cells, i.e., the period from the addition of GM-CSF, IL-4, OK-432, and PGE2 to induce mature dendritic cells (note that, since the time required for complete maturation thereafter is approximately 10 to 20 hours, the process corresponding to this time may also be included) takes too long, the usable period of the formulation will be shortened. Therefore, in order to complete the formulation within one week from the start of culture, it is preferable to pulse between 84 and 132 hours after the start of culture.More preferably, the pulse is performed between 94 hours and 132 hours, which is the range where the peak is -5%.

[0110] When α-galactosylceramide is pulsed into premature dendritic cells, the resulting preparation can exert its maximum effect in the recipient's body by pulsing it between 84 and 132 hours after the removal of non-adherent cells.

[0111] <Embodiment 8: Overview> Mainly, claim 8 describes a method for pulsing immature dendritic cells with α-galactosylceramide at a concentration of 300 ng / mL to 1000 ng / mL to induce NKT-stimulated dendritic cells, which are dendritic cells that stimulate Vα24-NKT cells. Hereinafter, in this embodiment, the timing of α-galactosylceramide pulsing is described, with the day on which monocytes collected from a recipient are placed in a culture vessel as day 0. In this embodiment, the timing of α-galactosylceramide pulsing is 120 hours after the start of culture, based on embodiment 5. The pulsing timing may be between 84 and 132 hours after the start of culture, or, as described in embodiment 4, 4 or 5 days after the day on which monocytes are placed in a culture vessel and the culture is started as day 0. Alternatively, as described in embodiments 2 and 3, pulsing may be performed on day 3 or 4, with the day on which a specific factor is added in the differentiation step as day 0, or 60 to 108 hours after the addition of the specific factor. Alternatively, as in the sixth and seventh embodiments, the pulse may be performed on the fourth or fifth day, with the day on which the non-adherent cells were removed from the culture vessel being day 0, or between 84 and 132 hours after the non-adherent cells were removed.

[0112] <Embodiment 8: (4) Pulse Step: Optimal Pulse Amount> In this embodiment 8, production is performed in accordance with the production method of the above-described embodiment 5, but differs from embodiment 5 in that the concentration of α-galactosylceramide to be pulsed is set to 300 ng / mL to 1000 ng / mL. In this embodiment 8, α-galactosylceramide was pulsed 120 hours after the start of culture, which is the timing when monocytes collected from the recipient were placed in the culture vessel.

[0113] Dendritic cell preparations produced by the production method of the present invention are expected to activate various immune system players by stimulating and activating Vα24-NKT cells to produce IFN-γ. To assess the efficacy of the preparation, non-adherent cells (lymphocytes (T cells, B cells, NK cells, NKT cells, etc.)) that have been removed in the non-adherent cell removal step (2) of the production method and separately cultured and stored are added to the preparation after completion of the preparation, followed by co-culture. The relationship between the concentration of α-galactosylceramide used for pulsing and the amount (concentration) of IFN-γ produced by NKT cells in the cultured non-adherent cells after co-culture is investigated, and the effectiveness is confirmed. The range of the pulse dose described above was determined in this manner.

[0114] In this embodiment, the time is expressed in hours starting from the time when monocytes collected from the recipient were placed in a culture vessel and culture was initiated. After the preparation was completed, non-adherent cells were added and co-cultured to confirm the effectiveness of the preparation. To verify the optimal pulse concentration, collected monocytes were divided into four groups, and four samples of dendritic cell preparations with different α-galactosylceramide pulse timings were prepared. 120 hours after the start of culture, monocytes collected from the recipient were pulsed with α-galactosylceramide at concentrations of 0 ng / mL (Condition 1), 100 ng / mL (Condition 2), 300 ng / mL (Condition 3), and 1000 ng / mL (Condition 4). To confirm the effectiveness of this preparation (evaluation of IFN-γ production concentration), non-adherent cells were added and co-culture was initiated 168 hours after the start of culture. The amount of IFN-γ produced in the samples under each condition was investigated on day 0 (the day co-culture was initiated), day 2, day 4, day 7, and day 14, with the day co-culture was designated as day 0.

[0115] IFN-γ was measured by ELISA using BIOLEGEND's ELISA MAX Deluxe Set Human IFN-γ.

[0116] Figure 5 shows the relationship between the concentration of α-galactosylceramide pulsed 120 hours after the initiation of culture of monocytes collected from recipients and the IFN-γ concentration measured on days 0 (the day of co-culture), 2, 4, 7, and 14 after the initiation of co-culture with non-adherent cells. The horizontal axis represents the number of days of co-culture, and the vertical axis represents the IFN-γ concentration (pg / mL). As described above, experiments were conducted under conditions 1 to 4, with the pulsed α-galactosylceramide concentration ranging from 0 to 1000 ng / mL. As shown in Figure 5, under conditions 1 (0 ng / mL) and 2 (100 ng / mL), the IFN-γ production concentration peaked on day 7 after the initiation of co-culture. Under conditions 3 (300 ng / mL) and 4 (1000 ng / mL), the production concentration peaked on day 4, with the peak value being equivalent to that under condition 2 (100 ng / mL). Conditions 3 (300 ng / mL) and 4 (1000 ng / mL) resulted in a peak production concentration three days earlier than the concentration condition (100 ng / mL) of embodiment 1 disclosed in the prior art (Patent Document 1, the same applies hereinafter), demonstrating earlier efficacy. Thus, when the α-galactosylceramide concentration used for pulsing is less than 300 ng / mL, the IFN-γ production peak is delayed, and pulsing at a concentration exceeding 1000 ng / mL results in the same results as 1000 ng / mL, resulting in wasted α-galactosylceramide. Therefore, it was found that the optimal α-galactosylceramide concentration is between 300 ng / mL and 1000 ng / mL. Furthermore, in a comparative experiment with the prior art (Patent Document 1) described below, when the same concentration of α-galactosylceramide was pulsed, the present invention, which pulses immature dendritic cells, achieved approximately four times the IFN-γ production concentration compared to the prior art (Patent Document 1), which pulses mature dendritic cells. This allows for the production of more IFN-γ than the prior art, and is expected to further activate the immune system and exert a greater anti-cancer effect.

[0117] According to this embodiment, the formulation produced by this production method can accelerate the peak of IFN-γ production in the recipient's body while maintaining the same peak value as under other conditions, and is expected to exert an anti-cancer effect more quickly. Furthermore, a higher IFN-γ production concentration can be obtained than in the prior art, and it is also expected to exert a greater anti-cancer effect.

[0118] <Embodiment 9: Overview> The blood of a recipient is added with any one of the dendritic cell preparations produced by the production methods shown in mainly claims 9 and 10, embodiments 1 to 8.

[0119] As explained in the first embodiment, adding the present preparation to the recipient's blood stimulates NKT cells to activate the innate immune system (improving immunity), and subsequently stimulates and activates the adaptive immune system, thereby improving immunity in the recipient's blood.

[0120] The recipient's blood may be extracted from the body and processed by adding the present product. By returning the processed blood (including the present product) to the recipient, it is expected that the recipient's immune system will be improved. Alternatively, the present product may be returned to the recipient's body and added to the blood in the body to improve the recipient's immune system. In addition, the recipient's blood may be replaced with the recipient's quasi-blood, which is the beneficiary's blood plus blood that can be transfused to the recipient.

[0121] <Results of Application to Human Bodies> A dendritic cell preparation manufactured under the conditions of Embodiment 4 of the present invention (culture was initiated on the day of blood collection, non-adherent cells were removed, GM-CSF and IL-4 were added 24 hours after the start of culture, and α-galactosylceramide was pulsed at 300 ng / mL on the fifth day) was administered to two recipients. The effects of the dendritic cell preparation of the present invention in the body have been described above. It activates NKT cells and activates various other immune-control cells through the production of IFN-γ. Because it has a particularly significant effect on NK cells, the NK activity value and IFN-γ amount after effective administration were examined. The results are shown in Figure 6. The preparation was administered to two recipients, one by subcutaneous injection (top row of the table) and the other by intravenous infusion (bottom row of the table). The NK activity value is a value indicating the activation of NK cells. NK activity increased from the third day after administration and remained higher than before administration on the seventh day. The lower limit of IFN-γ measurement is 0.1, and normally it is below 0.1. IFN-γ measurement results were 0.1 on the first day (day 0), but peaked on the second day after administration, with the numbers increasing significantly in both patients. This indicates that this dendritic cell preparation achieved its intended goal of activating NKT cells, rapidly increasing IFN-γ production, and also activating NK cells.

[0122] <Comparison with Prior Art: Overview> The prior art does not disclose the amount of IFN-γ produced (production concentration) in its specifications. Therefore, the inventors of the present invention produced a prototype cell composition following the method for producing a cell composition (corresponding to the dendritic cell preparation of the present application) described in prior art Patent Document 1, and conducted an experiment to compare the IFN-γ production concentration after co-culture with non-adherent cells including NKT cells.

[0123] <Comparison with the Prior Art: Preparation of a Comparative Example> To reproduce the prior art, mononuclear cells collected from a blood component were placed in a liquid medium in a culture vessel for 2 hours, and non-adherent cells (lymphocytes (T cells, B cells, NK cells, NKT cells, etc.)) were separated and cryopreserved. The day when the culture of the adherent cells was initiated after this placement was designated as day 0. The following day (day 1), GM-CSF and IL-4 were added to the culture medium for the adherent cells to differentiate them into immature dendritic cells. On day 5, GM-CSF, IL-4, PGE-2, and OK-432 were added to the immature dendritic cells to mature them. On the following day, day 6, the mature dendritic cells were pulsed with α-galactosylceramide (concentration 300 ng / mL).

[0124] <Comparison with Prior Art: Method for Confirming the Effect of Comparative Examples> On day 7, co-culture of the mature dendritic cells with the non-adherent cells collected on day 1 was initiated. The day on which co-culture was initiated (day 0), and the concentration of IFN-γ produced by the NKT cells in the non-adherent cells (pg / mL) were measured on days 2, 4, 7, and 14, with the day on which co-culture was initiated being designated as day 0.

[0125] <Comparison with Prior Art: Comparison of Effects Between Comparative Example and Embodiment of the Present Application> As described above, the IFN-γ production concentration after co-culture of dendritic cells and non-adherent cells, which was produced as a prototype in accordance with the prior art (based on the production method described in Patent Document 1, except that the pulsed α-galactosylceramide was used at a concentration of 300 ng / mL), was compared with the IFN-γ production concentration after co-culture of non-adherent cells and a dendritic cell preparation produced under Condition 3 of Embodiment 8 of the present application (pulsed α-galactosylceramide at a concentration of 300 ng / mL). Note that, to confirm the effects of the comparative example and the preparation produced under Condition 3 of Embodiment 8 of the present application, dendritic cells and non-adherent cells containing NKT cells derived from the same recipient were used, with the difference in cell number kept within a range that would not result in a significant difference.

[0126] <Comparison with Prior Art: Comparison of Effects Between Comparative Example and Embodiment of the Present Application: IFN-γ Production Concentration> Figure 7 shows the results of comparing IFN-γ production concentrations. The horizontal axis shows the number of days elapsed since the start of co-culture: 0 days (first day of initiation), 2 days, 4 days, 7 days, and 14 days, and the vertical axis shows the IFN-γ production concentration (pg / mL). In both the Comparative Example (prior art) and Condition 3 of Embodiment 8 of the present application, the IFN-γ production concentration increases on Day 4. In the prior art, the production concentration is slightly higher on Day 7 than on Day 4. Condition 3 of Embodiment 8 of the present application resulted in an IFN-γ production concentration that was approximately four times higher than that of the prior art.

[0127] <Comparison with Prior Art: Comparison of Effects Between Comparative Examples and Present Embodiments: IFN-γ Production Peak> Prior art Patent Document 1 describes the most preferable α-galactosylceramide concentration range as 80 to 120 ng / mL, and in Embodiment 1 of Patent Document 1, experiments were conducted using 100 ng / mL. Patent Document 1 does not verify the effectiveness of IFN-γ production. In experiments conducted by the present inventors, under Condition 2 of Embodiment 8 of the present invention, in which an α-galactosylceramide concentration (100 ng / mL) similar to that of Embodiment 1 of Patent Document 1 is pulsed, the IFN-γ production peak occurs on day 7 after co-culture. Therefore, although not described in Patent Document 1, the present inventors have discovered that by optimizing not only the α-galactosylceramide pulse timing but also the pulse concentration, it is possible to narrow down the range in which the effect is achieved earlier than in the prior art.

[0128] <Comparison with Prior Art: Superior Effects of the Present Invention> Compared to the Comparative Example (prior art), the present invention narrowed the range in which IFN-γ could be rapidly produced by pulsing immature dendritic cells with α-galactosylceramide and optimizing the timing and concentration of the pulse, thereby significantly improving the concentration of IFN-γ produced.

[0129] <Draft claim describing a treatment method for application in the U.S.>: (Tentative) A treatment method for a beneficiary who wishes to treat cancer, prevent cancer, or improve immunity using a dendritic cell preparation that stimulates NKT cells produced by the manufacturing method of the present invention can be described as follows. (1) a collection step of collecting monocytes or monocyte-containing peripheral blood from a beneficiary by apheresis or blood collection; (2) an adhesion step of placing the collected monocytes in a culture vessel using a liquid medium and leaving it to stand to allow a portion of the monocytes to adhere to the inner surface of the vessel; (3) a non-adherent cell removal step of removing non-adherent cells including monocytes other than those adhered to the inner surface of the culture vessel; (4) a differentiation step of adding a predetermined factor to the culture vessel to differentiate the monocytes adhered to the inner surface of the culture vessel into immature dendritic cells; (5) a pulsing step of pulsing α-galactosylceramide into the culture vessel in which the immature dendritic cells exist in a non-adherent state; and (6) an NKT-stimulatory dendritic cell induction step of inducing NKT-stimulatory dendritic cells, which are dendritic cells that stimulate NKT cells, from the immature dendritic cells. (7) A method of treatment using a dendritic cell preparation comprising dendritic cells that stimulate natural killer T (NKT) cells, the method comprising: (a) producing a dendritic cell preparation comprising dendritic cells that stimulate natural killer T (NKT) cells for the purpose of one or more of cancer treatment, cancer prevention, and immune enhancement by a production method comprising the steps of:

[0130] (Tentative) <Proposed Limitations of the Proposed Claim> (Tentative) One or more of the following limitations may be attached to the therapeutic method: (a) A therapeutic method in which, in the pulse step, α-galactosylceramide is pulsed 84 to 132 hours after monocytes are placed in a culture vessel using a liquid medium in the adhesion step (4 or 5 days after, with the time when the monocytes are placed being day 0). (b) A therapeutic method in which, in the pulse step, the concentration of α-galactosylceramide pulsed is 300 to 1000 ng / mL. (c) A therapeutic method in which, in the return step, the preparation is returned to the body of the beneficiary 156 hours or more after monocytes are placed in a culture vessel using a liquid medium in the adhesion step (7 days or more after, with the time when the monocytes are placed being day 0).

[0131] <Another embodiment: Cocktail preparation> The effect of a cocktail preparation of another embodiment when it is administered back into the body of a recipient is described below. In this example, the recipient has cancer cells in their body. In this other embodiment, collected monocytes are divided and placed in a culture vessel, separate from the preparation of the present invention. A preparation in which WT1 peptide is used as a ligand instead of α-galactosylceramide, which is pulsed as a ligand to immature dendritic cells in the present invention, is prepared in a separate vessel in parallel, and is configured to be present in the body of the recipient simultaneously with the preparation of the present invention.

[0132] Preparations using α-galactosylceramide as a ligand activate the recipient's innate immune system, improving immunity and indirectly activating the adaptive immune system. Preparations using the WT1 peptide, which is present in various cancers, as a ligand directly activate the adaptive immune system, targeting cancer cells.

[0133] <Effects of Cocktail Preparations> This alternative embodiment utilizes two types of preparations: one manufactured by the manufacturing method of the present invention, and the other manufactured by a similar method, in which the drug pulsing immature dendritic cells is pulsed with WT-1 peptide instead of α-galactosylceramide. Since nonspecific immunotherapy (preparation (ligand: α-galactosylceramide)) has already been explained, the following mainly describes the effect of the preparation with WT-1 peptide as the ligand, which directly targets the adaptive immune system, a different area. Cancer cells within the recipient's body form a barrier around them from immune function (due to immunosuppressive effects).

[0134] <Effect of α-galactosylceramide-pulsed preparation: NKT cell activation effect> The α-galactosylceramide-pulsed preparation activates NKT cells. Activated NKT cells have various effects on immune function.

[0135] <Action of activated NKT cells: adjuvant effect> Activated NKT cells produce cytokines (IFN-γ), which activate NK cells, macrophages, and killer T cells, enhancing their ability to attack cancer. They also activate various immune cells. Killer T cells and helper T cells are activated by pulsing dendritic cells with the WT1 peptide, which exhibits specific immune activity, as a ligand. These activated NK cells and activated B cells are simultaneously favorably influenced by the pathway of nonspecific immune activity, resulting in a synergistic effect that is greater than the simple addition of effects. This is one of the features of this embodiment.

[0136] <Action of activated NKT cells: apoptosis-inducing effect on cancer cells> Activated NKT cells produce a type of serine protease that breaks down the DNA of cancer cells, causing apoptosis in the cancer cells.

[0137] <Action of activated macrophages: Cancer cell phagocytosis by macrophages> Activated macrophages phagocytose cancer cells and dead cancer cells.

[0138] <Action of proliferated and activated macrophages: Antigen presentation by macrophages> Activated NKT cells proliferate and activate macrophages. Proliferated and activated macrophages fragment cancer cells they have ingested through phagocytosis and display them on the cell surface. In other words, they perform an antigen presentation function that presents antigens from cancer cells. Macrophages then present these antigens to helper T cells.

[0139] <Cancer antigen presentation by dendritic cells: Cancer antigen presentation by dendritic cells> Immature dendritic cells take up cancer antigens, mature, and differentiate into mature dendritic cells, which present cancer antigens to helper T cells and killer T cells. This action is an anti-cancer effect that normally occurs in the body, but the action of activated NKT cells provides a greater anti-cancer effect than usual. Because this cancer antigen is presented after dendritic cells and macrophages phagocytose the patient's own cancer cells, it is expected to be more effective than preparations that use artificial antigens as ligands. This action is also one of the factors that contribute to the synergistic effect of the cocktail preparation of the present invention.

[0140] <Effect of WT1 peptide-pulsed preparations: cancer antigen presentation effect> WT1 peptide-pulsed preparations present and activate the WT1 peptide, a cancer antigen, to helper T cells and killer T cells. This allows the killer T cells to recognize cancer cells as targets for attack, and the helper T cells activate the killer T cells, which then produce cytokines that activate NK cells, as described below, and promote antibody production by B cells.

[0141] <The action of activated helper T cells: instructing them to attack cancer cells> Activated helper T cells produce cytokines (IFN-γ) and instruct killer T cells to attack cancer cells based on the information contained in these cytokines. In addition, the effects of cytokines activate NK cells, B cells, and macrophages, thereby enhancing their ability to attack cancer.

[0142] <Function of activated helper T cells: instructing the production of antibodies against cancer antigens (e.g., WT1)> Activated helper T cells produce cytokines and, based on the information contained in the cytokines, instruct B cells to produce antibodies against cancer antigens (e.g., WT1).

[0143] <Action of activated killer T cells: Killer T cells' attack on cancer cells> This is the main force that directly attacks cancer cells. Activated killer T cells recognize and bind to WT1 expressed on cancer cells, creating holes in the cell membrane and causing necrosis of the cancer cells. They also produce substances such as TNF-β (tumor necrosis factor, a type of cytokine), which induces apoptosis in cancer cells. In this way, the direct attack of killer T cells on cancer cells is a powerful anti-cancer effect that attacks cancer cells from both the outside and the inside.

[0144] <Action of activated killer T cells: Destruction of new blood vessels> The WT1 gene is expressed in blood vessels newly formed by cancer cells, and killer T cells presented with the cancer antigen (WT1) attack not only cancer cells but also newly formed blood vessels. This destroys the newly formed blood vessels, reducing the supply of nutrients to cancer cells and suppressing their proliferation. This action is also one of the factors that causes the cocktail preparation of this other embodiment to have a synergistic effect.

[0145] <Action of activated NK cells: Action of NK cells to attack cancer cells> NK cells are stimulated and activated by IFN-γ produced by helper T cells in addition to IFN-γ produced by activated NKT cells, and exhibit a cytotoxic response against cancer cells, attacking them.

[0146] <Function of activated B cells: production of cancer antibodies> Activated B cells produce antibodies against cancer antigens (e.g., WT1) and attack cancer cells. These antibodies have functions such as suppressing cancer cell proliferation by binding to cancer cells and promoting attack by serving as a marker for other immune cells (e.g., NK cells and killer T cells).

[0147] As described above, by simultaneously introducing a formulation with α-galactosylceramide as a ligand and a formulation with WT1 peptide as a ligand into the recipient's body, it is possible to activate the adaptive immune system targeting cancer cells more quickly than by using only the formulation of the present invention (the formulation with α-galactosylceramide as a ligand). By directly activating both the innate and adaptive immune systems, a synergistic effect can be achieved, rather than a simple additive effect. Therefore, when used for cancer treatment, this formulation is expected to have a faster and more effective effect than using it alone.

[0148] <Effects> The method of producing a dendritic cell preparation for stimulating NKT cells, which involves injecting monocytes back into the body of a recipient from whom the preparation was collected, has been improved over the prior art (Patent Document 1) by identifying conditions for stimulating NKT cells to produce greater amounts of IFN-γ and narrowing the range of α-galactosylceramide concentrations that result in faster IFN-γ production. This allows for greater efficacy in cancer treatment and other conditions, utilizing both the innate and adaptive immune systems. This provides the excellent benefit of producing a dendritic cell preparation that can be expected to have even greater therapeutic effects. Furthermore, the dendritic cell preparation can also be effective in improving the immune system of healthy individuals. Furthermore, by producing the dendritic cell preparation from the recipient's own monocytes, a safe preparation can be obtained without the risk of rejection.

Claims

1. A method for producing a dendritic cell preparation containing dendritic cells that stimulate natural killer T cells (hereinafter referred to as "NKT cells") for the purpose of one or more of cancer treatment, cancer prevention, and improvement of immunity, comprising: (1) an adhesion step of placing monocytes collected from a recipient in a culture vessel using a liquid medium and allowing the vessel to stand to allow some of the monocytes to adhere to the inner surface of the vessel; (2) a non-adherent cell removal step of removing non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel; (3) a differentiation step of adding a predetermined factor to the culture vessel to differentiate the monocytes adhered to the inner surface of the culture vessel into immature dendritic cells; (4) a pulsing step of pulsing α-galactosylceramide into a culture vessel in which the immature dendritic cells predominantly exist; (5) a step of inducing NKT-stimulatory dendritic cells, which are dendritic cells that stimulate NKT cells, from immature dendritic cells; A method for producing an NKT cell-stimulating dendritic cell preparation for injecting the monocytes back into the body of a recipient from whom the monocytes were collected to stimulate NKT cells, comprising the steps of:

2. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is carried out on the 3rd or 4th day, with the day on which the predetermined factor was added in the differentiation step (3) being considered as day 0.

3. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is carried out 60 to 108 hours after the addition of the predetermined factor in the differentiation step (3).

4. 2. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is carried out on the 4th or 5th day, counting the day on which the monocytes collected from the recipient in the adhesion step (1) are placed in the culture vessel as day 0.

5. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is carried out between 84 and 132 hours after the monocytes collected from the recipient in the adhesion step (1) are placed in a culture vessel.

6. 2. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is performed on the 4th or 5th day, taking the day on which non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel are removed in the non-adherent cell removal step (2), as day 0.

7. The method for producing a dendritic cell preparation according to claim 1, wherein the pulsing step (4) is carried out between 84 hours and 132 hours after the removal of non-adherent cells, including monocytes, other than cells adhered to the inner surface of the culture vessel in the non-adherent cell removal step (2).

8. The method for producing a dendritic cell preparation according to any one of claims 1 to 7, wherein the concentration of α-galactosylceramide pulsed in the pulsing step (4) is 300 to 1000 ng / mL.